Abstract:OBJECTIVE:Plasma free metanephrines (MNs) have been widely used as an initial test for pheochromocytoma and paraganglioma (PPGL). PPGL without MNs elevation has been reported on rare occasions. The objective of this study was to analyze the clinical profile of sporadic PPGL patients with normal MNs.METHODS:In the study, 104 patients with sporadic PPGL diagnosed by histopathology in Peking University First Hospital from March 2015 to January 2020 were enrolled. All the patients had plasma MNs result, of whom, eight (7.69%) were with normal MNs. The reasons for their medical visits, clinical manifestations, the levels of plasma free MNs, 3-methoxytyramine (3-MT), catecholamines and chromogranin A (CgA), and the imaging findings were documented. Their preoperative diagnosis, perioperative medical management, and intraoperative blood pressure were analyzed. All the data mentioned above were compared with the MNs elevated group. The postoperative follow-up for MNs normal patients were applied.RESULTS:For the eight PPGL patients with normal plasma MNs, the most common clinical symptoms were sweating (3/8), abdominal and back pain (3/8), headache (2/8), palpitations (2/8), and fatigue (2/8). There were no significant differences in plasma free 3-MT and catecholamines' diagnostic positive rate between the MNs normal group and MNs elevated group, but the rate for plasma CgA was significantly decreased in the MNs normal group (2/5 vs. 41/43, P=0.005). No significant difference was found for the incidence of typical findings by enhanced CT between the two groups. In these eight MNs normal patients, six were diagnosed with PPGL by the previous history of PPGL, typical symptoms and CT findings, or elevation of 3-MT, CgA levels or positive results of PET-CT; two patients were misdiagnosed as nonfunctioning adenoma or primary aldosteronism. All these MNs normal patients underwent preoperative management with alpha adrenergic receptor blockers, of whom, one had an average intraoperative arterial pressure < 60 mmHg during surgery. The median follow-up time for the eight patients was 1.5 (0.5－4.5) years. No evidence of new tumors was found on the enhanced CT scans. Two MNs normal patients' plasma 3-MT and (or) CgA decreased to normal.CONCLUSION:For patients with adrenal or retroperitoneal tumors, typical symptoms or a previous history of PPGL, normal plasma MNs is not a sufficient exclusion for PPGL. Plasma 3-MT, catecholamine, CgA results and the imaging findings are helpful for the diagnosis of PPGL. We recommend patients with suspected MNs normal PPGL take alpha adrenergic receptor blockers as preoperative blockade, but should avoid overdose. Postoperative follow-up for patients with normal MNs should focus on the positive biochemical markers before surgery.

Alterations and clinical value of peripheral lymphocyte subsets and inflammatory factors in paragangliomas

The Prognostic Value of Platelet-Lymphocyte Ratio and Neutrophil-Lymphocyte Ratio in the Treatment Response and Survival of Patients with Peripheral T-cell Lymphoma.

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

Platelet-Lymphocyte and Neutrophil-Lymphocyte Ratios Are Prognostic Markers for Pheochromocytomas and Paragangliomas.

Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.

PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma.

Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma

Metastatic Pheochromocytomas and Abdominal Paragangliomas

Prediction model for pheochromocytoma/paraganglioma using nCounter assay

The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives

Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution

The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease

Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study

Hot Trends in Pheochromocytoma and Paraganglioma: Are We Getting Closer to Personalized Dynamic Prognostication?

A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas

The clinical feathers of phaechromocytoma and paraganglioma with normal plasmal free MNs

Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma

Novel Alternative Tools for Metastatic Pheochromocytomas/paragangliomas Prediction

Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors

[Clinical Profile of Pheochromocytoma and Paraganglioma with Normal Plasma Free Metanephrines].

Proportion of peripheral lymphocyte subsets correlates with the progression-free survival and metastatic status of pancreatic neuroendocrine tumour patients